016580.KS
Strong BuyFull HouseAI screen passWhan In Pharm Co.,Ltd. · Healthcare · South Korea · $137M
KRW 10,250 +1.3% · close 2 Oct · scored 3 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
The company meets the 50/50/50 eligibility criteria with strong value and momentum scores. Absent any adverse regulatory signals or evidence of distress, it aligns with our criteria for stable compounders.
ABOUT WHAN IN PHARM CO.,LTD.
Read
Whan In Pharm Co.,Ltd. is a South Korean pharmaceutical company engaged in the development, manufacturing, and marketing of ethical drugs, over-the-counter medicines, and health functional foods. Its competitive moat is derived from a diversified product portfolio and an established domestic market presence. The company focuses on addressing various therapeutic needs and expanding its consumer health offerings within South Korea.
FINANCIAL SUMMARY (KRW)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 198.9B | 230.4B | 259.6B | 255.2B | 8.7% | 273.7B | 283.3B | 311.2B | 10.4% |
| EPS (KRW) | 1,567 | 1,950 | 1,531 | 857.00 | -18.2% | 857.85 | 1,253 | 1,428 | 29.1% |
| Shares | 15.3M | 15.3M | 15.3M | 18.5M | +21.1% | 18.5M | — | — | — |
| Debt | 249.9M | 632.0M | 413.7M | 679.0M | 39.5% | 568.6M | — | — | — |
| Equity | 333.5B | 358.2B | 376.0B | 421.0B | 8.1% | — | — | — | — |
| Op CF | 16.9B | 23.2B | 20.7B | 9.0B | -18.7% | 17.7B | — | — | — |
| Inv CF | -38.9B | -9.4B | -18.1B | 4.7B | — | — | — | — | — |
| Fin CF | -5.1B | -5.2B | -5.1B | 6.6B | — | — | — | — | — |
Calmer than 82% of stocks we rank over the past year (25% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 016580.KS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 016580.KS | Whan In Pharm Co.,Ltd.(you) | $137M | 95 | Strong Buy |
| 234080.KS | JW Lifescience Corporation | $126M | 94 | Strong Buy |
| 023910.KQ | Daihan Pharmaceutical Co.,Ltd. | $114M | 90 | Strong Buy |
| 005500.KS | Samjin Pharmaceuticals Co., Ltd. | $172M | 90 | Strong Buy |
| 001630.KS | Chong Kun Dang Holdings Corp. | $132M | 86 | Strong Buy |
| 096760.KS | JW Holdings Corporation | $221M | 100 | Strong Buy |
| 001540.KQ | Ahn-Gook Pharmaceutical Co., Ltd. | $84M | 100 | Strong Buy |
| 008490.KS | Suheung Co., Ltd. | $163M | 83 | Strong Buy |
| 033270.KS | Korea United Pharm Inc. | $206M | 87 | Strong Buy |
| 002800.KQ | Sinsin Pharmaceutical Co., Ltd | $51M | 93 | Strong Buy |
Peer medians: ROE -0.3% · P/E 17.6x · Gross margin 43.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.